| External factors: | Melatonin |
| Aging type: | Prevent |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Aging |
| Experiment: | SA-β-gal activity assay//Flow cytometry |
| Description: | The percentage of SA-β-gal-positive cells showed a declining dose-dependent tendency in response to melatonin, in which the ratio decreased to 64.7 ± 3.2% at 10 nM, 54.4 ± 2.3% at 1 μM, and 24.3 ± 5.7% at 100 μM . The cell cycle distribution results showed that melatonin-treated BM-MSCs exhibited a significantly increased proportion in the S phase . |
| Regulatory pathway: | SIRT1 |
| R-EF-Pathway: | Upregulation |
| Official symbol(s): | SIRT1 |
| Pathway experiment: | qRT-PCR//Immunofluorescence//Western blot |
| Pathway description: | On the other hand, treatment with 100 μM melatonin increased the SIRT1 mRNA level by 1.8 ± 0.2-fold higher than the H2O2 group.exposure to H2O2 inhibited SIRT1 protein expression but treatment with melatonin recovered it. Further experiments revealed that the protein level of SIRT1 in H2O2-treated BM-MSCs was significantly down-regulated to 42.8 ± 6.3% compared with the control, but treatment with melatonin upregulated the level of SIRT1. |
Annotation: